SAINT LAURENT, Quebec, Dec. 21, 2011 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) ("IntelGenx") today announced that it has entered into a co-development and commercialization agreement with Par Pharmaceutical, Inc. ("Par") for a new product utilizing one of IntelGenx' proprietary oral drug delivery platforms. Product description and financial terms were not disclosed.
